Notify me when Sands Capital Alternatives, LLC files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ABOS | Acumen Pharmaceuticals, Inc. | Common Stock, par value $0.0001 per share | 5.6% | $3,861,295 | 3,417,075 | Sands Capital Alternatives, LLC | 30 Jun 2025 | ||
| KVYO | Klaviyo, Inc. | Series A Common Stock, par value $0.001 per share | 4.9% | $127,806,680 | 4,416,264 | SANDS FRANK M. | 31 Mar 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|